CHU DIJON - Hopital le Bocage

Dijon 21079

0 studies enrolling now · 1 studies all time

What they study most

Atopic Dermatitis

Studies at this site

• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed